Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2021Annals of Internal Medicine

Pulmonary Hypertension

View Full Paper
Ask AI
Bookmark
Share

Design

Review

Authors

DPDavid PochVascular MedicineJMJess MandelUC San Diego Health System

Discussion

Loading...

Member takes

Implication

Aids etiology-based PH management in practice; leaves open standardization of emerging therapies in future guidelines.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Poch et al. (2021) studied this question.

synapsesocial.com/papers/69d8112fa2a48916bbbeecc2https://doi.org/10.7326/aitc202104200
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction2015 · 397 citations
  2. 2Long-Term Outcome after Pulmonary Thromboendarterectomy1999 · 316 citations
  3. 3Tadalafil Therapy for Pulmonary Arterial Hypertension2009 · 1,109 citations
  4. 4Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension2013 · 326 citations
  5. 5Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)2015 · 228 citations